Acumen Pharmaceuticals (ABOS): Short-Term Debt to Equity Ratio

Acumen Pharmaceuticals - graphic logo of issuer ABOS

Acumen Pharmaceuticals (ABOS) is developing cutting-edge treatments for Alzheimer's disease, securing profitability through long-term reservation of production capacities. Business growth is driven by the potential of the ACU193 drug and global demand stemming from demographic shifts. The market price on GURU.Markets, as confirmed by the chart, shows a value of 0.56, which correlates with investor confidence in Daniel O'Connell's leadership during the antibody development phase.

Acumen Pharma (ABOS) Ratio of Short-Term Indebtedness to Capital: for the period 07/04/2022 - 10/29/2026

Analytical breakdowns for Acumen Pharmaceuticals

- price and consensus price forecast:
Stock Price Acumen Pharma|ABOS - Average Forecast Price
- market capitalization data:
Market Valuation Acumen Pharmaceuticals Inc.|ABOS - Enterprise Value
- book capitalization data:
Net Assets per Single Share Acumen Pharmaceuticals|ABOS - Accounting Value of Company|Market Value to Book Value Ratio acumenpharm.com|ABOS - Company Assets
- debt and liquidity data:
Total Debt to Capital Acumen Pharmaceuticals|ABOS - Long-Term Debt to Capital|Short-Term Debt to Capital Acumen Pharmaceuticals, Inc.|ABOS - Company Total Debt|Debt to Book Value Acumen Pharmaceuticals Inc.|ABOS - Company Long-Term Debts|Company Short-Term Debt Acumen Pharmaceuticals
Fundamental company analysis:Acumen Pharma
Brand item of acumenpharm.com

The lack of stable cash flow due to Acumen Pharmaceuticals (ABOS) focusing on clinical stages of antibody development makes the company dependent on external financing. This chart of the short-term liabilities-to-equity ratio allows for an assessment of loans with a maturity of up to one year relative to equity, revealing risks of rising debt service costs during a period of high Fed rates and determining the stability of the capital structure.

Competing companies

Biogen Corp - Short-Term Debt to Capital|Current Liabilities to Capital Neurocrine Corp NBIX|Short-Term Debt to Equity Ratio RGC (Regencell Bioscience)|axsome.com - Short-Term Debt to Capital|Short-Term Debt to Equity ACADIA Pharmaceuticals Inc. (ACAD)|XENE: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity VKTX|Supernus Corp (SUPN) - Current Liabilities to Capital|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital denalitherapeutics.com|Short-Term Debt to Capital HRMY (Harmony Biosciences Holdings, Inc.)|Short-Term Debt to Equity Ratio Biohaven Ltd BHVN|Short-Term Debt to Equity Ratio AMLX (Amylyx)|Trevi Corp - Short-Term Debt to Capital|PRAX: Short-Term Debt to Equity|AVXL - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital CBLL|PRTA (Prothena Biosciences) - Current Liabilities to Capital|Short-Term Debt to Equity Alector Inc. (ALEC)|Short-Term Debt to Capital Ratio Annexon Biosciences Inc. (ANNX)|Omeros Corporation (OMER) - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NGNE (neurogene.com)|AC Immune SA (ACIU) - Short-Term Debt to Equity|Current Liabilities to Equity Voyager Therapeutics Inc VYGR|Short-Term Debt to Capital Neumora Therapeutics Inc (NMRA)|SCLX - Ratio of Short-Term Indebtedness to Capital|TVGN: Short-Term Debt to Capital|ACOG (Alpha Cognition Inc.) - Short-Term Debt to Capital|CGTX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IKT|Short-Term Debt to Equity SAVA (Cassava)|Short-Term Debt to Equity Ratio assertiotx.com (ASRT)|Short-Term Debt to Capital COYA (Coya Therapeutics)|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|OVID: Short-Term Debt to Capital|CRVO - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital ATHE|Current Liabilities to Capital Clene|PEPG (PepGen Inc) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital jupiterneurosciences.com (JUNS)|Short-Term Debt to Equity Ratio Relmada Therapeutics, Inc.|Short-Term Loans to Capital Ratio Annovis Bio Inc (ANVS)|Short-Term Debt to Capital GRCE|Short-Term Debt to Capital Coefficient Firefly Neuro AIFF|KLTO: Short-Term Debt to Capital|NRSN - Short-Term Debt to Equity Ratio|RVPH: Short-Term Debt to Capital|MTVA (MetaVia) - Short-Term Debt to Capital|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Equity HSDT|PASG (Passage Bio, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient bionomics.com.au (NEUP)|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Athira Pharma Inc ATHA|ADXN - Short-Term Debt to Capital|ALZN: Short-Term Debt to Equity|Short-Term Debt to Equity CYCN|PTIX (Protagenic Therapeutics, Inc.) - Current Liabilities to Capital|KTTA: Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient CRGT|Short-Term Debt to Equity Avenue Therapeutics, Inc ATXI|Short-Term Debt to Capital Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|CARA: Short-Term Debt to Capital|CHRO - Current Liabilities to Capital|Eliem - Short-Term Debt to Equity Ratio|ITCI: Short-Term Debt to Capital|Short-Term Debt to Equity Longboard Pharma LBPH|MRNS (Marinus Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGN (NKGen Biotech, Inc.)|Current Liabilities to Capital neurobopharma.com|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Trevena, Inc - Short-Term Debt to Capital|VIGL - Short-Term Debt to Equity Ratio|Anew Medical, Inc. - Short-Term Debt to Equity Ratio|CERE: Short-Term Debt to Capital